Apical membrane antigen 1 (AMA-1) (AMA-1)

Plasmodium falciparum Apical Membrane Antigen 1 (AMA-1) is a highly conserved type I integral membrane protein essential for the invasion of host erythrocytes by malaria merozoites (3, 5). It is localized in the micronemes of the parasite and is translocated to the surface just prior to invasion (3, 10). AMA-1 consists of an ectodomain divided into three subdomains (I, II, and III), a transmembrane region, and a cytoplasmic tail (5, 6). Domain III, specifically, is a disulfide-constrained region that plays a crucial role in the structural integrity of the protein and is a target for inhibitory antibodies (6). During invasion, AMA-1 interacts with the Rhoptry Neck Protein 2 (RON2) to form a "moving junction," which is the structural interface through which the parasite enters the red blood cell (10, 13). Because of its indispensable role in the parasite life cycle, AMA-1 is a primary candidate for blood-stage malaria vaccines and the development of inhibitory peptides or small molecules (12, 13). However, the high degree of genetic polymorphism, particularly in domains I and II, presents a significant challenge for achieving broad-spectrum protection (5, 6). Domain III is relatively more conserved but still faces challenges related to immune evasion and the need for high antibody titers to achieve effective neutralization (6).

Other names

PfAMA1Apical membrane antigen 1AMA-1 domain IIIEctodomain domain IIIPF3D7_1133400

Inhibition of merozoite invasion by blocking the interaction between AMA-1 and Rhoptry Neck Protein 2 (RON2), thereby preventing the formation of the moving junction required for parasite entry into host erythrocytes.